Claudia Zimmermann

Banque Lombard Odier & Cie SA (Investment Management) (Lombard Odier-IM) is the investment management division of Banque Lombard Odier & Cie, a subsidiary of Compagnie Lombard Odier SCmA in Switzerland. The firm was founded in 2002 when Lombard Odier & Cie and Darier Hentsch & Cie. merged. They are headquartered in Geneva with branches and representative offices throughout Switzerland, Europe, the Americas, Asia Pacific and the Middle East. Lombard Odier-IM provides private banking and asset management services to institutions, family-owned businesses and high-net worth individuals. They also provide a range of support services for independent intermediaries.

Nura, Inc. discovers and develops pharmaceutical products. It offers products for the treatment of neurodegenerative diseases such as Parkinson's & Alzheimer's diseases and behavioural disorders such as depression, anxiety, schizophrenia, obesity, and addiction. The company was founded in August 2003 and is headquartered in Seattle, WA.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Aravis Venture II LP invests in biotechnological start-ups with growth potential.

Fondation Fournier Majoie pour l'Innovation EtUtPub is a social services provider based in Brussels, Belgium. The Belgian company provides social services.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

HYT SA designs and manufactures watches. Its products include skull, H0-H4 watches. The firm engages in the development, marketing, purchasing, selling, promotion and distribution of watches, jewelry, and luxury items. The company was founded by Lucien Vouillamoz, Emmanuel Savioz, Ion Schiau and Patrick Berdoz in December 2010 and is headquartered in Neuchatel, Switzerland.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

Quadia SA (Quadia) is an independent investment firm founded in 2010. The firm is headquartered in Switzerland.

Inception IBD, Inc. provides therapeutics services. It creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded by Eric Ogier-Denis, Yoram Bouhnik, Xavier Treton and Jacques Mizrahi in 2011 and is headquartered in San Diego, CA.

Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom.

TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland.

Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.

LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France.

The Swiss company was founded by Emmanuel Savioz, Patrick Berdoz, Christophe Bonny, and Fabrice Chenaux. The CEO is Franco Merkling.

DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation.

Strongwind Holding AG owns and operates wind park. The company is headquartered in Zurich, Switzerland.